Publications by authors named "I Ashankyty"

Article Synopsis
  • Breast cancer is caused by abnormal breast cells that can form tumors, which can spread and become deadly if not treated.
  • The study aimed to understand the molecular changes from Ductal Carcinoma In Situ (DCIS) to Invasive Ductal Carcinoma (IDC) by identifying important hub genes related to this transition and potential treatments.
  • Ten key hub genes linked to tumor progression were identified, with CDK1 and DTL being significant, and the study found that the anti-inflammatory compound Fisetin effectively binds to these genes, suggesting it could help in targeting treatment for breast cancer.
View Article and Find Full Text PDF

The majority of the well-known pharmacogenomics research used in the medical sciences contributes to our understanding of medication interactions. It has a significant impact on treatment and drug development. The broad use of pharmacogenomics is required for the progress of therapy.

View Article and Find Full Text PDF

Unlabelled: Hemophilia A (HA) is an X-linked recessive disorder that results from mutations in the factor VIII gene (FVIII). Most affected patients are males due to the inheritance of mutations in the FVIII gene from their mothers. Females are mostly found to be carriers unless they inherited the mutation from both parents.

View Article and Find Full Text PDF

To understand complex diseases, high-throughput data are generated at large and multiple levels. However, extracting meaningful information from large datasets for comprehensive understanding of cell phenotypes and disease pathophysiology remains a major challenge. Despite tremendous advances in understanding molecular mechanisms of cancer and its progression, current knowledge appears discrete and fragmented.

View Article and Find Full Text PDF

Background: Iron deficiency anemia (IDA) is a global health problem affecting the quality of life of more than 2 billion individuals. The current practice guidelines diagnose and monitor IDA via conventional hematological and iron biomarkers, which take several months before they are corrected under an iron-treatment plan. Reticulocyte hemoglobin equivalent (Ret-He) is used as a marker in most new hematology analyzers to assess iron incorporation into erythrocyte hemoglobin directly.

View Article and Find Full Text PDF